Oregon Clinical Trials Report — May 2026

For Oregonians considering participation in clinical research, May 2026 presents a crucial window of opportunity, particularly for trials nearing their enrollment deadlines. Across the state, 71 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 9 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, neurological conditions, and other health challenges are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stage IV lung cancer
• Depression
• Glaucoma
• Prostate cancer
• Ovarian cancer
• Advanced breast cancer
• Breast cancer
• Acute undifferentiated leukemia
• Acute myeloid leukemia
• Acute blood loss anemia

A Focused Month for New Research in Oregon

This May, Oregon saw the launch of 3 new clinical trials, a notable shift compared to the 15 trials that opened in March 2026. While the number of new studies is lower this month, the trials introduced are significant, addressing critical health areas and backed by major sponsors.

All 3 of this month's new trials are concentrated in Portland, reinforcing the city's role as a central hub for medical research in the state. Despite this concentration, Oregon continues to offer a broad array of research opportunities, with a total of 1,170 clinical trials currently recruiting across 37 cities and 521 research sites statewide.

One of the most notable new initiatives is a substantial Phase 3 drug trial sponsored by Novo Nordisk A/S. This study aims to make a significant impact on two widespread conditions:

• NCT07567001: "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This large-scale trial is designed to enroll 5,610 participants globally, evaluating the safety and effectiveness of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.

Other new trials opening this month are exploring:

• Prostate cancer (sponsored by Blue Earth Diagnostics)
• Very preterm and extremely preterm birth (sponsored by the University of Washington)

These new studies include 2 drug trials, 1 diagnostic test, and 1 dietary supplement trial, indicating a diverse approach to medical advancement.

Opportunities for Diverse Participants

Clinical trials in Oregon are designed to include a wide range of participants. Of the new trials launched this month, 1 includes children, offering opportunities for younger individuals to contribute to research. Additionally, 2 of the new studies are open to older adults, ensuring that senior populations have ample avenues to engage with medical science. One new trial is specifically designed for male participants.

For individuals without a specific medical condition, there are still numerous opportunities to contribute. While none of the 3 new trials this month are seeking healthy volunteers, there are currently 104 total clinical trials recruiting healthy participants across Oregon. These studies play a vital role in establishing baseline data and understanding how new treatments affect individuals without pre-existing conditions.

The research landscape in Oregon benefits from a mix of sponsors. This month's new trials are primarily driven by industry, with 2 studies sponsored by pharmaceutical companies like Novo Nordisk A/S and Blue Earth Diagnostics. The University of Washington also contributes as an academic sponsor, highlighting the collaborative nature of medical research.

As we move further into May, the focus remains on the ongoing enrollment in these critical studies, alongside the preparation for future research initiatives that will continue to address a broad spectrum of health challenges across Oregon.